Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
27
11
2021
accepted:
11
03
2022
revised:
24
02
2022
pubmed:
30
3
2022
medline:
22
7
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
The RECIST-based response variably matches the clinical benefit of systemic therapies for liver metastatic uveal melanoma (LMUM). The aims were to determine whether the tumour growth rate (TGR) can help predict the survival in patients with LMUM and to provide information for the management of first-line systemic treatment. This retrospective study included 147 (training: n = 110, validation: n = 37) patients with LMUM treated with first-line systemic treatment between 2010 and 2021. Two TGR-derived parameters were calculated, TGR TGR The use of TGR
Sections du résumé
BACKGROUND
The RECIST-based response variably matches the clinical benefit of systemic therapies for liver metastatic uveal melanoma (LMUM). The aims were to determine whether the tumour growth rate (TGR) can help predict the survival in patients with LMUM and to provide information for the management of first-line systemic treatment.
METHODS
This retrospective study included 147 (training: n = 110, validation: n = 37) patients with LMUM treated with first-line systemic treatment between 2010 and 2021. Two TGR-derived parameters were calculated, TGR
RESULTS
TGR
DISCUSSION
The use of TGR
Identifiants
pubmed: 35347325
doi: 10.1038/s41416-022-01793-8
pii: 10.1038/s41416-022-01793-8
pmc: PMC9296460
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-267Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5.
doi: 10.1016/j.ophtha.2011.01.040
Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561–8.
doi: 10.1097/CMR.0000000000000575
Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192–7.
doi: 10.1016/j.ejso.2009.02.016
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44.
doi: 10.1136/bjophthalmol-2016-309034
Pelster MS, Gruschkus SK, Bassett R, Gombos D, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599–607.
doi: 10.1200/JCO.20.00605
Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Carrión L, Martín-Algarra S, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39:586–98.
doi: 10.1200/JCO.20.00550
Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall Survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196–206.
doi: 10.1056/NEJMoa2103485
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1—Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.
doi: 10.1016/j.ejca.2016.03.081
Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res. 2014;20:246–52.
doi: 10.1158/1078-0432.CCR-13-2098
Carter BW, Murthy R, Balmes G, Wachter EA, Patel S. Response assessment of metastatic uveal melanoma treated with rose bengal disodium. Ann Oncol. 2019;30:xi46.
doi: 10.1093/annonc/mdz451.033
Shoushtari AN, Collins L, Espinosa E, Sethi H, Stanhope S, Abdullah S, et al. 1757O Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients. Ann Oncol. 2021;32:S1210.
doi: 10.1016/j.annonc.2021.08.1702
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer. 2011;47:2512–6.
doi: 10.1016/j.ejca.2011.06.012
Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: The GREPONET-2 Study. Clin Cancer Res. 2019;25:6692–9.
doi: 10.1158/1078-0432.CCR-19-0963
Ramtohul T, Ait Rais K, Gardrat S, Barnhill R, Román-Román S, Cassoux N, et al. Prognostic implications of mri melanin quantification and cytogenetic abnormalities in liver metastases of uveal melanoma. Cancers. 2021;13:2728.
doi: 10.3390/cancers13112728
McShane LM, Altman DG, Sauerbrei W, Taube S, Gion M, Clark G, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Rev Clin Oncol. 2005;2:416–22.
on behalf of the CLARINET Study Group, Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, et al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer. 2019;19:66.
doi: 10.1186/s12885-018-5257-x
Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies: PD-1 Blockade in Uveal Melanoma. Cancer. 2016;122:3344–53.
doi: 10.1002/cncr.30258
Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8:e000331.
doi: 10.1136/jitc-2019-000331
Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7:299.
doi: 10.1186/s40425-019-0800-0
Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea. Ophthalmology. 2000;107:1443–9.
doi: 10.1016/S0161-6420(00)00182-2
Ferté C, Koscielny S, Albiges L, Rocher L, Soria J-C, Iacovelli R, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD Phase 3 Trial Data. Eur Urol. 2014;65:713–20.
doi: 10.1016/j.eururo.2013.08.010
ten Berge DMHJ, Hurkmans DP, den Besten I, Kloover JS, Mathijssen RHJ, Debets RJEMA, et al. Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. ERJ Open Res. 2019;5:00179–2019.
doi: 10.1183/23120541.00179-2019
Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30:1370–80.
doi: 10.1093/annonc/mdz176
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.
doi: 10.1056/NEJMoa1709030
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801.
doi: 10.1056/NEJMoa1802357
Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668–74.
doi: 10.1200/JCO.2017.75.6270
Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018;19:229–39.
doi: 10.1016/S1470-2045(17)30846-X
Kim JH. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget. 2016;7:13680–7.
doi: 10.18632/oncotarget.7322
Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67:3970–5.
doi: 10.1158/0008-5472.CAN-06-3822
Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, et al. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer. 2021;9:e002350.
doi: 10.1136/jitc-2021-002350
Maitland ML, Wilkerson J, Karovic S, Zhao B, Flynn J, Zhou M, et al. Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation. Clin Cancer Res. 2020;26:6464–74.
doi: 10.1158/1078-0432.CCR-20-1493
Gerlee P. The model muddle: in search of tumor growth laws. Cancer Res. 2013;73:2407–11.
doi: 10.1158/0008-5472.CAN-12-4355